Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

prednisoLONE ophthalmic cycloSPORINE ophthalmic

Applies to: bromfenac / prednisolone ophthalmic, cyclosporine ophthalmic

MONITOR: Coadministration with eye drops containing corticosteroids may potentiate the immunosuppressant effects of cyclosporine eye drops.

MANAGEMENT: Caution is recommended if corticosteroid-containing eye drops and cyclosporine-containing eye drops are used concomitantly. Eye examination at 6-monthly intervals are recommended if cyclosporine eye drops are intended for long-term use.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."

Drug and food interactions

Moderate

bromfenac food

Applies to: bromfenac / prednisolone ophthalmic

ADJUST DOSE: In-vivo studies have demonstrated that the absorption of bromfenac is greatly reduced if the drug is taken within three and one-half hours following a high fat meal. The concomitant administration of a high fat meal has led to a 75% reduction in peak plasma concentrations and a 60% reduction in total area under the curve. The mechanism has not been described.

MANAGEMENT: An increased dosage of bromfenac (from 25 to 50 mg) may be needed if a high fat meal is consumed. The clinician may want to warn the patient about subtherapeutic analgesic effects if high fat meals are regularly consumed.

References (1)
  1. "Product Information. DurAct (bromfenac)." Wyeth-Ayerst Laboratories

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.